Corporate presentation
Logotype for Viking Therapeutics Inc

Viking Therapeutics (VKTX) Corporate presentation summary

Event summary combining transcript, slides, and related documents.

Logotype for Viking Therapeutics Inc

Corporate presentation summary

11 Nov, 2026

Pipeline and market

  • VK2735 is a dual GLP-1/GIP agonist for obesity, in Phase 3 testing as both a subcutaneous injection and an oral tablet; VK3019 is an amylin agonist in Phase 1.

  • VANQUISH subcutaneous Phase 3 trials are fully enrolled; SUNRISE oral Phase 3 trials began in 4Q26, with topline data expected in 2028.

  • Obesity affects 1B+ adults globally and is associated with 200+ comorbidities; current therapy penetration is below 5%, and most patients discontinue within one year.

  • Obesity market projections show 16% CAGR and $150B+ in 2035E sales; VK2735 is positioned to pursue share with oral and injectable formulations.

VK2735 subcutaneous results

  • In the 13-week VENTURE Phase 2 trial, weight loss reached 14.7% from baseline and 13.1% placebo-adjusted at the 15 mg dose; all dose groups were significant vs. placebo.

  • Weight loss was progressive across all cohorts, with no plateau through Week 13; statistical significance vs. placebo began in Week 1 and continued through Week 13.

  • In the VK2735-102 maintenance study, Week 21 weight loss reached 17.8% at 17.5 mg and 18.7% at 20 mg; continued 17.5 mg weekly dosing produced 21.7% loss at Week 33.

  • After transition from weekly dosing, up to 96.7% of Week 21 weight loss was maintained with every-other-week dosing and up to 90.2% with monthly dosing through Week 33.

  • VANQUISH-1 enrolled 4,500+ participants and VANQUISH-2 approximately 1,000; both completed enrollment, with data expected in 2H27.

VK2735 oral results

  • In the 13-week oral Phase 2 study, mean weight loss reached 12.2%; loss was progressive without a plateau, and doses above 15 mg were statistically significant vs. placebo at all time points.

  • Most weight loss was maintained for three weeks after dosing ended; an exploratory 90 mg-to-30 mg daily maintenance cohort continued gradual weight loss through Week 13.

  • The oral study reported 99% of GI adverse events as mild or moderate; doses up to 60 mg had GI tolerability similar to placebo, and rates generally declined over time.

  • SUNRISE-1 and SUNRISE-2 began in 4Q26, each targeting 560 participants over 68 weeks; data are expected in 2028.

  • A subcutaneous-to-oral maintenance study is underway, with data expected in 2027.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Viking Therapeutics